SG11202108900WA - Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer - Google Patents

Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer

Info

Publication number
SG11202108900WA
SG11202108900WA SG11202108900WA SG11202108900WA SG11202108900WA SG 11202108900W A SG11202108900W A SG 11202108900WA SG 11202108900W A SG11202108900W A SG 11202108900WA SG 11202108900W A SG11202108900W A SG 11202108900WA SG 11202108900W A SG11202108900W A SG 11202108900WA
Authority
SG
Singapore
Prior art keywords
azetidobenzodiazepine
dimers
conjugates
cancer
treatment
Prior art date
Application number
SG11202108900WA
Other languages
English (en)
Inventor
Philip Wilson Howard
Thais Cailleau
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1903541.9A external-priority patent/GB201903541D0/en
Priority claimed from GBGB2000121.0A external-priority patent/GB202000121D0/en
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of SG11202108900WA publication Critical patent/SG11202108900WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
SG11202108900WA 2019-03-15 2020-03-13 Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer SG11202108900WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1903541.9A GB201903541D0 (en) 2019-03-15 2019-03-15 Compounds and conjugates
GBGB2000121.0A GB202000121D0 (en) 2020-01-06 2020-01-06 Compounds and conjugates
PCT/EP2020/056761 WO2020187721A1 (fr) 2019-03-15 2020-03-13 Dimères d'azétidobenzodiazépine et conjugués les comprenant destinés à être utilisés dans le traitement du cancer

Publications (1)

Publication Number Publication Date
SG11202108900WA true SG11202108900WA (en) 2021-09-29

Family

ID=69845376

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108900WA SG11202108900WA (en) 2019-03-15 2020-03-13 Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer

Country Status (14)

Country Link
US (1) US20220160881A1 (fr)
EP (1) EP3938372B1 (fr)
JP (1) JP7520870B2 (fr)
KR (1) KR20210139270A (fr)
CN (1) CN113631560A (fr)
AU (1) AU2020242747A1 (fr)
BR (1) BR112021018260A2 (fr)
CA (1) CA3130174A1 (fr)
ES (1) ES2967878T3 (fr)
IL (1) IL286326A (fr)
MX (1) MX2021010477A (fr)
SG (1) SG11202108900WA (fr)
WO (1) WO2020187721A1 (fr)
ZA (1) ZA202105931B (fr)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU757510C (en) 1998-08-27 2003-09-11 Medimmune Limited Pyrrolobenzodiazepines
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
CA2558195C (fr) 2004-03-01 2012-11-06 Spirogen Limited Derives de 11-hydroxy-5h-pyrrolo[2,1-c][1,4] benzodiazepine-5-one en tant qu'intermediaires cles pour la preparation de pyrrolobenzodiazepines substituees c2
CA2580141C (fr) 2004-09-23 2013-12-10 Genentech, Inc. Anticorps et conjugues produits avec de la cysteine
CA2604805C (fr) 2005-04-21 2014-05-27 Spirogen Limited Pyrrolobenzodiazepines
ATE527262T1 (de) 2006-01-25 2011-10-15 Sanofi Sa Neue tomaymycin derivate enhaltende zytotoxische mittel
PE20090245A1 (es) 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
KR101622412B1 (ko) 2007-10-19 2016-05-18 제넨테크, 인크. 시스테인 조작된 항-ｔｅｎｂ２ 항체 및 항체 약물 접합체
US9242013B2 (en) * 2010-04-15 2016-01-26 Seattle Genetics Inc. Targeted pyrrolobenzodiazapine conjugates
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
AU2013328628B2 (en) * 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
KR101819404B1 (ko) 2012-10-12 2018-02-28 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3313854A1 (fr) 2015-06-23 2018-05-02 Bristol-Myers Squibb Company Formes macrocycliques dimères des benzodiazépines, leurs conjugués, préparation et utilisations
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CA3042054A1 (fr) 2016-11-10 2018-05-17 Medimmune, Llc Molecules de liaison specifiques d'asct2 et leurs utilisations
RS63502B1 (sr) * 2017-04-18 2022-09-30 Medimmune Ltd Konjugati pirolobenzodiazepina

Also Published As

Publication number Publication date
IL286326A (en) 2021-10-31
WO2020187721A1 (fr) 2020-09-24
EP3938372A1 (fr) 2022-01-19
CA3130174A1 (fr) 2020-09-24
EP3938372B1 (fr) 2023-10-25
MX2021010477A (es) 2021-10-01
CN113631560A (zh) 2021-11-09
AU2020242747A1 (en) 2021-09-16
ZA202105931B (en) 2024-01-31
JP2022524880A (ja) 2022-05-10
BR112021018260A2 (pt) 2021-11-23
US20220160881A1 (en) 2022-05-26
KR20210139270A (ko) 2021-11-22
JP7520870B2 (ja) 2024-07-23
ES2967878T3 (es) 2024-05-06

Similar Documents

Publication Publication Date Title
IL270814A (en) Transplanted cytokine antibody proteins and methods of use for cancer treatment
EP3250609A4 (fr) Agents de liaison à l'il13ra alpha 2 et leur utilisation dans le traitement du cancer
IL277854A (en) Conjugates of antibody and drug and their use for cancer treatment
IL266623A (en) A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer
IL281495A (en) Quinuclidine-3-one derivatives and their use in cancer treatment
EP4066837A4 (fr) Utilisation de bi853520 dans le traitement du cancer
IL280510A (en) Antibody-drug conjugates for use in the treatment of metastatic brain tumor
IL276768A (en) Antibody-antidrug-tissue factor conjugates and their use in cancer treatment
IL274122A (en) Antibody-antidrug-tissue factor conjugates and their use in cancer treatment
IL280617A (en) Antibody-drug conjugates against tissue factor and their use for cancer treatment
IL286334A (en) Modified microRNAs and their use in cancer treatment
EP3897725A4 (fr) Combinaison de radioimmunothérapie et de thérapie de point de contrôle immunitaire dans le traitement du cancer
IL280830A (en) Bracelets for use in cancer treatment methods
IL304245A (en) Phospholipid-flaveglin conjugates and methods of using them for targeted cancer treatment
EP3999092A4 (fr) Agents et méthodes de polythérapie contre le cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
GB202317288D0 (en) Pyrrolopyridone derivatives useful in the treatment of cancer
IL308058A (en) History Molfentin is useful in the treatment of cancer
IL288178A (en) Combined gmci and ddri treatment for cancer
IL286326A (en) Azetidobenzodiazepine dimers and conjugates containing them for use in cancer therapy
EP3891123A4 (fr) Analogues d'oligo-benzamide et leur utilisation dans le traitement du cancer
IL277038A (en) Bexarotane derivatives and their use for cancer treatment
GB201810635D0 (en) Peptides and cancer treatment
IL277112A (en) Compounds for inhibiting protein degradation and methods of use thereof in the treatment of cancer
AU2019902712A0 (en) Inhibitors and use thereof in cancer treatment